Jeil Pharmaceutical Co.,Ltd (KRX:271980)

KRX:271980 Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	46,830	53,476	32,991	31,446	25,963	3,893
Short-Term Investments	4,576	3,980	2,667	142.46	2,040	2,695
Cash & Short-Term Investments	51,406	57,455	35,658	31,589	28,003	6,588
Cash Growth	48.16%	61.13%	12.88%	12.80%	325.06%	-51.27%
Accounts Receivable	154,618	160,467	150,955	137,807	129,424	141,176
Other Receivables	12,504	13,440	15,171	15,454	15,265	15,747
Receivables	167,122	173,908	166,126	153,262	146,689	156,922
Inventory	98,735	104,427	109,768	99,151	102,458	109,311
Prepaid Expenses	147.74	214.62	327.84	291.88	186.71	167.88
Other Current Assets	6,770	7,031	5,167	7,348	7,336	4,524
Total Current Assets	324,182	343,036	317,046	291,641	284,672	277,513
Property, Plant & Equipment	143,948	146,166	137,041	138,402	125,710	115,547
Long-Term Investments	10,743	8,342	7,343	6,798	5,032	1,920
Other Intangible Assets	8,210	4,994	4,320	3,888	3,762	4,095
Long-Term Accounts Receivable	0	0	-0	0	0	-
Long-Term Deferred Tax Assets	7,139	7,428	5,359	172.39	1,452	3,321
Long-Term Deferred Charges	7,929	8,378	8,561	5,494	-	-
Other Long-Term Assets	4,056	7,356	7,656	10,496	5,858	7,267
Total Assets	506,207	525,700	487,326	456,892	426,486	409,663
Accounts Payable	111,214	134,562	144,338	151,641	153,084	143,363
Accrued Expenses	171.08	178.21	160.74	99.91	29.33	24.88
Short-Term Debt	76,477	71,000	64,772	40,576	24,166	30,419
Current Portion of Long-Term Debt	-	-	-	2,500	6,125	6,125
Current Portion of Leases	1,932	1,971	1,946	1,832	1,915	1,598
Current Income Taxes Payable	3,140	3,588	448.24	1,049	114.57	3,432
Other Current Liabilities	72,626	80,391	92,710	62,667	36,509	33,096
Total Current Liabilities	265,560	291,690	304,375	260,366	221,943	218,058
Long-Term Debt	-	-	-	3,999	8,977	7,656
Long-Term Leases	2,168	2,725	4,452	5,443	6,617	3,506
Other Long-Term Liabilities	197.01	197.01	938.52	23,170	20,339	459.46
Total Liabilities	280,818	306,383	316,499	293,003	259,139	237,184
Common Stock	7,352	7,352	7,352	7,352	7,352	7,352
Additional Paid-In Capital	183,075	206,223	155,296	155,296	155,296	149,117
Retained Earnings	-26,469	-52,296	-19,660	-20,321	-10,414	2,841
Treasury Stock	-4,829	-4,829	-4,829	-4,829	-4,432	-3,622
Comprehensive Income & Other	33,610	31,699	20,410	20,410	20,410	16,706
Total Common Equity	192,739	188,150	158,570	157,909	168,213	172,394
Minority Interest	32,649	31,167	-1,538	-2,312	-866.16	85.04
Shareholders' Equity	225,389	219,317	170,828	163,889	167,347	172,479
Total Liabilities & Equity	506,207	525,700	487,326	456,892	426,486	409,663
Total Debt	80,577	75,695	71,170	54,350	47,800	49,304
Net Cash (Debt)	-29,170	-18,240	-35,513	-22,761	-19,797	-42,716
Net Cash Per Share	-2001.87	-1251.75	-2437.13	-1561.68	-1355.11	-2922.88
Filing Date Shares Outstanding	14.57	14.57	14.57	14.57	14.58	14.61
Total Common Shares Outstanding	14.57	14.57	14.57	14.57	14.58	14.61
Working Capital	58,621	51,345	12,671	31,275	62,729	59,455
Book Value Per Share	13227.12	12912.16	10882.20	10836.83	11533.52	11800.20
Tangible Book Value	184,529	183,156	154,250	154,021	164,451	168,299
Tangible Book Value Per Share	12663.71	12569.44	10585.71	10570.02	11275.56	11519.87
Land	53,698	53,698	40,613	40,586	30,106	23,821
Buildings	67,057	105,484	103,864	103,864	102,213	102,747
Machinery	9,671	88,787	88,622	82,315	76,560	72,000
Construction In Progress	-	4,724	3,070	3,717	2,390	584.93

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.